Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: An overview and network meta-analysis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  Kew, Kayleigh M ^a   Li, Tianjing ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; STEROID;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84949231293     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010178.pub2     Document Type: Article

References (30)

1. Appleton S, Jones T, Poole P, Pilotto L, Adams R, Lasserson Toby J, et al.Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD001387.pub2]
2. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. European Respiratory Journal : official journal of the European Society for Clinical Respiratory Physiology 2004;23(6):932-46. [0903-1936: (Print)]
3. Barr RG, Bourbeau J, Camargo Carlos A. Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2]
4. Beeh KM, Beier J. The Short, the Long, and the "Ultra-long": Why Duration of Bronchodilator Action Matters in Chronic Obstructive Pulmonary Disease. Advances in Therapy 2010;27(3):150-9.
5. Berger WE, Nadel JA. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. Respiratory Medicine 2008; Vol. 102, issue 2:173-88. [0954-6111: (Print)]
6. Decramer ML, Hanania NA, Lotvall, JO, Yawn BP. The safety of long-acting β2-agonistsin the treatment of stable chronic obstructive pulmonary disease. International Journal of COPD 2013;8:53-64.
7. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Statistics in Medicine 2010;29(7-8):932-44.
8. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Guobing L, Ades AE. NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials. 2011; last updated April 2012. http://www.nicedsu.org.uk (accessed 3/10/13).
9. Dias S, Sutton AJ, Ades AE, Welton NJ. A Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials. Medical Decision Making 2012 Oct 26 [Epub ahead of print].
10. Dong Y, Lin H, Shau W, Wu Y, Chang C, Lai M. Comparative safety of inhaled medications inpatients with chronic obstructive pulmonary disease:systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013;68:48-56.
11. Effing T, Monninkhof Evelyn EM, van der Valk Paul PDLPM, Zielhuis Gerhard GA, Walters EH, van der Palen Job J, et al.Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD002990.pub2]
12. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com (accessed 3/10/13).
13. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
14. Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Research Synthesis Methods 2012; Vol. 3, issue 2:98-110. [: 1759-2887]
15. Hutchinson A, Brand C, Irving L, Roberts C, Thompson P, Campbell D. Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure. Internal Medicine Journal 2010;40(5):364-71.
16. Lacasse Y, Goldstein R, Lasserson Toby J, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD003793.pub2]
17. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011/05/24 2011; Vol. 66, issue 8:699-708. [1468-3296: (Electronic)]
18. Lu G, Ades A. Assessing evidence consistency in mixed treatment comparisons. Journal of the American Statistical Association 2006;101:447-59.
19. Moen MD. Indacaterol: in chronic obstructive pulmonary disease. Drugs 2010;70(17):2269-80. [0012-6667: (Print)]
20. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease, Costing report, Implementing NICE guidance. http://guidance.nice.org.uk/CG101/CostingReport/pdf/English (accessed 3/10/13).
21. Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD005305.pub3]
22. Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R. Safety of long-acting β-agonists in stable COPD: A systematic review. Chest 2008;133(5):1079-87.
23. Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest 2009;136(4):1029-38. [1931-3543: (Electronic)]
24. Sestini P, Renzoni E, Robinson S, Poole P, Ram FSF. Short-acting beta2-agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD001495]
25. Singh S, Loke YK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 2010;5:189-95.
26. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society. Series B (Statistical Methodology) 2002;64(4):583-639.
27. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al.A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine 2008;359(15):1543-54.
28. van der Meer Regina M, Wagena E, Ostelo Raymond WJG, Jacobs Annelies JE, van Schayck O. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2001, Issue 1. [DOI: 10.1002/14651858.CD002999]
29. White IR, Barrett JK, Jackson D, Higgins JPT. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Research Synthesis Methods 2012;3(2):111-25. [: 1759-2887]
30. World Health Organization. Chronic Respiratory Diseases. http://www.who.int/respiratory/en/ (accessed 3/10/13).